Tissue Repair Ltd · ASX:TRP
Tissue Repair — Shareholder Meeting (October 2023)
24 slides from Tissue Repair's shareholder meeting presentation, Oct 26, 2023
Slide 1: Tissue Repair Limited AGM Company Update
For personal use only Tissue Repair Limited AGM Company Update • Progress on TR987® Phase 3 trials • Sales commence for TR Pro+TM October 2023
Slide 2: Key Updates since IPO
TR987® - Cleared to enter Phase 3 by the FDA. A core Clinical Operations capability has been established with first patient randomisation planned for early Q2 2024 Key Updates since IPO Glucoprime® - Patented platform technology. Applicable to many types of • Feedback on the Phase 3 VLU trial protoc
Slide 3: TR is achieving key milestones within its existing funding envelope
Despite some delays TR is achieving key milestones . . . within its existing funding envelope TR987® TR Pro+TM Phase 3 trial approval Product launch in May 2023 Intellectual Property Funding For personal use only received by FDA ✓ First patent published (12 June ✓ Founder led ethos to capital ✓ Gluc
Slide 4: Glucoprime technology platform applicable to multiple wound types
TRs technology platform Glucoprime ® is applicable for multiple types of wounds in humans and animals Receptors on macrophages within damaged tissue recognize the Glucoprime® - containing hydrogel. Macrophages are the ‘guard’ cells that protect against invaders. For personal use only Two receptors,
Slide 5: Medium-term focus on commercialisation of two products
The medium-term focus is on commercialisation of two products for two discrete applications, each having significant markets and compelling economics . . . success in either is a significant value milestone An FDA-approved label for the treatment Horizon 2 For personal use only of chronic wounds is
Slide 6: TR987 Chronic Wounds
For personal use only TR987® CHRONIC WOUNDS
Slide 7: New data: meta-analysis of Phase 2 trials
NEW DATA A recent meta-analysis on 147 patients from two Phase 2 trials has confirmed a strong signal of efficacy and demonstrated a 60% reduction in wound size vs placebo control (p=0.03). A strong data point, providing further confidence on a successful Phase 3 outcome For personal use only In Mar
Slide 8: Example of closed venous leg ulcer after TR987
An example of a closed venous leg ulcer following treatment by TR987 ® during the Phase 2B trial For personal use only
Slide 9: TR987 key advantages over current products
TR987® for chronic wounds - key advantages over current products • No drug or biologic appears to have been approved in chronic wounds since REGRANEX gel in 1997, and as Strong efficacy such a drug label with high quality clinical data drives reimbursement and is highly prized For personal use only
Slide 10: TR Pro+ (Aesthetic and Minor Medical Procedures)
For personal use only TR Pro+TM (AESTHETIC AND MINOR MEDICAL PROCEDURES)
Slide 11: Phase 2B study showed significant improvement in skin quality
The Phase 2B study using laser skin resurfacing showed a statistically significant improvement in skin quality at Day 28 Wrinkling Elastosis In this group, 85% of responders in the active In this group, 75% of responders in the active group achieved a wrinkling score improvement group achieved an el
Slide 12: Phase 2B study published in peer reviewed journal
The Phase 2B study was recently published in a peer reviewed journal (Wu et al. 2022) For personal use only Study Author's concluded “In summary, this study demonstrates the potential of TR Pro+TM 0.1% gel to significantly improve skin quality outcomes after fractionated ablative laser resurfacing w
Slide 13: Redness and irritation example following TR Pro+ treatment
A typical example of redness and irritation following treatment by TR Pro+ TM in the Phase 2B laser skin resurfacing study Close to double the For personal use only improvement in skin quality as measured by elastosis and wrinkling Days post- vs standard of care & placebo procedure Day 1 Day 28
Slide 14: Real-world evidence study patient ratings
In a real-world evidence study (2022), 100% of patients rated TR Pro+TM as good or better than previous post-procedure aftercare product used. . . 85% of patients rated it as 4/5 stars on healing and skin quality For personal use only Patient responses at days 6 and 28 Similar or better compared to
Slide 15: TR Pro+ opportunity to deliver on an unmet need
TR Pro+ TM - an opportunity to deliver on an unmet need in current therapy following aesthetic and minor medical procedures For personal use only • • • • • • • • • • • •
Slide 16: Post procedure topical market has no clear product lead
The post procedure topical market has no clear product lead, and is potentially a USD1b* market globally Skincare and cosmetics are significant global markets with strong CAGRs • Total revenues from the global cosmetics market are set to hit $103.8 billion in 2023 • Skincare was the leading category
Slide 17: Intellectual Property
Intellectual Property Glucoprime® meets the FDA criteria of A New Chemical Entity (NCE). There is no drug substance currently approved globally for any indication based on Tissue Repair’s engineered molecule. This provides the potential for exclusivity preventing competitors from replicating the tec
Slide 18: Tissue Repair. Strategy on a Page
Tissue Repair. Strategy on a Page Stage of clinical development Market Product Strategy Commercial Preclinical Ph 1 Ph 2A Ph 2B Ph 3 • Achieve FDA and TGA For personal use only 2024 approval as a topical Progression to commence #1 Chronic drug for use in venous Ph3 following partnering TR987® leg ul
Slide 19: Capital Structure Update
Capital Structure Update All seed and founders escrowed for up to 2 years For personal use only Shares on Issue 60,464,843 Options on issue 21,954,292 $0.49 (Average exercise price) Cash as at 30 June 2023 $21.4m All options issued pre IPO, did not dilute IPO shareholders Cash backing per share $0.3
Slide 20: Appendix: Additional clinical data - Phase 2B Trial
For personal use only Appendix Additional clinical data - Phase 2B Trial
Slide 21: Phase 2B ITT Summary Results
Phase 2B ITT Summary Results. Partial and complete healing metrics. For personal use only
Slide 22: Phase 2B Per Protocol Summary Results
Phase 2B Per Protocol Summary Results. Partial and complete healing metrics. For personal use only
Slide 23: For personal use only
For personal use only
Slide 24: Important notice and disclaimer
For personal use only Important notice and disclaimer